ATXN2 and amyotrophic lateral sclerosis: Intermediate Q27–Q33 expansions in ATXN2 are associated with the risk of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD) [10,11,12,13,14], with tauopathies and Parkinson’s variants such as progressive supranuclear palsy (PSP) [15,16].